Table 1.
Clinical and demographic features of natalizumab- and fingolimod-treated MS patients.
| Natalizumab | Fingolimod | p-value | |
|---|---|---|---|
| Age at disease onset (y) | 27.7 ± 9.4 | 28.7 ± 9.8 | 0.7 |
| Sex (female/male) | 32/11 | 28/15 | 0.4 |
| Disease duration at study inclusion (m) | 114.0 ± 94.0 | 110.4 ± 98.4 | 0.9 |
| Criterion of prescription (A/B) | 32/11 | 36/7 | 0.3 |
| Relapses during the 12 months before study inclusion | 1.4 ± 0.8 | 1.2 ± 0.6 | 0.4 |
| EDSS at study inclusion | 2.0 (1.0–6.5) | 2.0 (1.0–6.5) | 1.0 |
| Number of previous treatments | 1 (0–5) | 1 (0–6) | 0.3 |
| Previous treatment: none | 11 | 7 | 0.5 |
| Glatiramer acetate | 5 | 7 | |
| Interferon | 25 | 25 | |
| Cyclophosphamide | 1 | 3 | |
| Mitoxantrone | 0 | 1 | |
| Azathioprine | 1 | 0 |
EDSS, Expanded Disability Status Scale; m, months; MS, multiple sclerosis; y, years.